{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:54:35Z","timestamp":1773424475946,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.clinthera.2008.05.002","type":"journal-article","created":{"date-parts":[[2008,6,14]],"date-time":"2008-06-14T08:54:58Z","timestamp":1213433698000},"page":"884-901","source":"Crossref","is-referenced-by-count":57,"title":["Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: A meta-analysis of eight randomized, placebo-controlled, 12-week trials"],"prefix":"10.1016","volume":"30","author":[{"given":"Roja","family":"Rahimi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shekoufeh","family":"Nikfar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Abdollahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2008.05.002_bib1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1041-2972.2005.00011.x","article-title":"Recognizing and managing patients with irritable bowel syndrome","volume":"17","author":"Croghan","year":"2005","journal-title":"J Am Acad Nurse Pract"},{"issue":"Suppl 11","key":"10.1016\/j.clinthera.2008.05.002_bib2","first-page":"S1","article-title":"Evidence-based position statement on the management of irritable bowel syndrome in North America","volume":"97","author":"American College of Gastroenterology Functional Gastrointestinal Disorders Task Force","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2008.05.002_bib3","first-page":"495","article-title":"Prevalence of irritable bowel syndrome: A community survey","volume":"54","author":"Wilson","year":"2004","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.clinthera.2008.05.002_bib4","first-page":"1118","article-title":"Prevalence of irritable bowel syndrome in the French population according to the Rome I criteria","volume":"26","author":"Bommelaer","year":"2002","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.clinthera.2008.05.002_bib5","first-page":"20","article-title":"IBS-review and what's new","volume":"8","author":"Foxx-Orenstein","year":"2006","journal-title":"MedGenMed"},{"key":"10.1016\/j.clinthera.2008.05.002_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003460.pub2","article-title":"Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome","volume":"2","author":"Quartero","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2008.05.002_bib7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2217\/14750708.2.2.237","article-title":"Effects of sildenafil on rat irritable bowel syndrome","volume":"2","author":"Zamani","year":"2005","journal-title":"Therapy"},{"key":"10.1016\/j.clinthera.2008.05.002_bib8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0002-9270(02)05656-3","article-title":"An evidence-based approach to the management of irritable bowel syndrome in North America","volume":"97","author":"Brandt","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2008.05.002_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2036.2006.02938.x","article-title":"Systematic review: The efficacy of treatments for irritable bowel syndrome-a European perspective","volume":"24","author":"Tack","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2008.05.002_bib10","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/ajhp\/62.7.700","article-title":"Rationale for using serotonergic agents to treat irritable bowel syndrome","volume":"62","author":"Baker","year":"2005","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2008.05.002_bib11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000090309","article-title":"Drugs acting on serotonin receptors for the treatment of functional GI disorders","volume":"24","author":"Tonini","year":"2006","journal-title":"Dig Dis"},{"issue":"Suppl 5","key":"10.1016\/j.clinthera.2008.05.002_bib12","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.1097\/01.mcg.0000156113.14974.f5","article-title":"Psychotherapeutics and serotonin agonists and antagonists","volume":"39","author":"Mertz","year":"2005","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.clinthera.2008.05.002_bib13","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1365-2982.2004.00550.x","article-title":"Options for patients with irritable bowel syndrome: Contrasting traditional and novel serotonergic therapies","volume":"16","author":"Johanson","year":"2004","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.clinthera.2008.05.002_bib14","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/j.1572-0241.2007.01282.x","article-title":"A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS","volume":"102","author":"Krause","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2008.05.002_bib15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1572-0241.2005.40365.x","article-title":"A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS","volume":"100","author":"Chang","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2008.05.002_bib16","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/j.1572-0241.2004.30509.x","article-title":"Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome","volume":"99","author":"Chey","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2008.05.002_bib17","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/archinte.161.14.1733","article-title":"A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome","volume":"161","author":"Camilleri","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2008.05.002_bib18","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0140-6736(00)02033-X","article-title":"Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebocontrolled trial","volume":"355","author":"Camilleri","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2008.05.002_bib19","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1046\/j.1365-2036.1999.00610.x","article-title":"Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist","volume":"13","author":"Camilleri","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2008.05.002_bib20","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1046\/j.1365-2036.2000.00786.x","article-title":"Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome","volume":"14","author":"Thumshirn","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2008.05.002_bib21","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1111\/j.1572-0241.2002.07111.x","article-title":"Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome","volume":"97","author":"Olden","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2008.05.002_bib22","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S1542-3565(04)00284-8","article-title":"Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: Analysis of two controlled trials","volume":"2","author":"Lembo","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2008.05.002_bib23","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1111\/j.1572-0241.2001.04128.x","article-title":"Alosetron controls bowel urgency and provides global symptom improvement in women with diarrheapredominant irritable bowel syndrome","volume":"96","author":"Lembo","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2008.05.002_bib24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2982.2003.00389.x","article-title":"Efficacy of alosetron in irritable bowel syndrome: A metaanalysis of randomized controlled trials","volume":"15","author":"Cremonini","year":"2003","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.clinthera.2008.05.002_bib25","series-title":"Randomised Controlled Trials.","author":"Jadad","year":"1998"},{"key":"10.1016\/j.clinthera.2008.05.002_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1365-2036.2000.00684.x","article-title":"A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome","volume":"14","author":"Bardhan","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2008.05.002_bib27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2982.2006.00861.x","article-title":"Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment?","volume":"19","author":"Camilleri","year":"2007","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.clinthera.2008.05.002_bib28","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1572-0241.2006.00459.x","article-title":"Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: Systematic review of clinical trials and post-marketing surveillance data","volume":"101","author":"Chang","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2008.05.002_bib29","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1572-0241.2001.03626.x","article-title":"Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients","volume":"96","author":"Wolfe","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2008.05.002_bib30","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1046\/j.1365-2036.1999.00678.x","article-title":"Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients","volume":"13","author":"Jones","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2008.05.002_bib31","first-page":"77","article-title":"Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: A meta-analysis of randomized controlled trials","volume":"4","author":"Rahimi","year":"2008","journal-title":"Arch Med Sci"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808001720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291808001720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,12]],"date-time":"2019-05-12T03:37:51Z","timestamp":1557632271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291808001720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0149291808001720"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2008.05.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}